Asuragen, Max Planck Society, Rockefeller University deal

The university granted Asuragen a nonexclusive license to microRNAs for use in cancer diagnostics. In a separate deal, Garching Innovation GmbH, the technology transfer arm of Max Plank, granted Asura...